Prof Rajiv Khanna
Prof. Rajiv Khanna obtained his doctorate degree from India and undertook his post-doctoral training at the Queensland Institute of Medical Research (QIMR), Brisbane Australia. He is the founding Director/Coordinator of Australian Centre for Vaccine Development (now named as QIMR Berghofer Centre for Immunotherapy and Vaccine Development). He holds Senior Principal Research Fellowship from the National Health and Medical Research Council of Australia and is also appointed as Honorary Professor at the University of Queensland and Griffith University, Brisbane, Australia. Prof. Khanna is a Fellow of Australian Academy of Health and Medical Sciences. He has extensive expertise in immunotherapy clinical trials, cancer immunology and vaccine development. The major goals of his research group are to obtain a deeper understanding of the mechanisms by which human immune response to viruses and cancers may be generated, augmented and applied to control these diseases. Over the last two decades, his group has successfully translated his research towards the development of novel T cell-based immunotherapeutic strategies for the treatment of cancer patients and transplant recipients. Prof. Khanna has been appointed as a consultant to Atara Biotherapeutics (US), CSL Ltd, Cellestis Ltd and Oxford Immunotech (UK) for the development of novel immunotherapeutics, diagnostic technologies and vaccines. He is also appointed on Scientific Advisory Board of Atara Biotherapeutics. Prof. Khanna has been invited by International Transplant Society to participate in the development of guidelines for the clinical management of cytomegalovirus infection in solid organ transplant patients. Prof. Khanna’s group is collaborating with international biopharmaceutical organizations to develop a prophylactic vaccine against human cytomegalovirus which is associated with post-transplant infectious complications and birth defects in new born babies.